Trial Profile
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs Travoprost (Primary) ; Timolol
- Indications Glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Alcon
- 30 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Nov 2013 New trial record